Magnetar Financial LLC Buys Shares of 21,936 Illumina, Inc. (NASDAQ:ILMN)

Magnetar Financial LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, HoldingsChannel reports. The firm purchased 21,936 shares of the life sciences company’s stock, valued at approximately $2,931,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bleakley Financial Group LLC acquired a new position in shares of Illumina during the fourth quarter valued at approximately $751,000. Zacks Investment Management purchased a new stake in shares of Illumina during the third quarter valued at $2,924,000. Van ECK Associates Corp boosted its holdings in shares of Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after buying an additional 22,718 shares during the period. Strategic Financial Concepts LLC purchased a new position in Illumina during the 4th quarter worth approximately $1,464,000. Finally, Allworth Financial LP boosted its position in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock worth $1,001,000 after acquiring an additional 6,263 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 0.2 %

NASDAQ:ILMN opened at $84.79 on Friday. The company has a market cap of $13.43 billion, a price-to-earnings ratio of -11.04, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 52-week low of $80.18 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock’s fifty day moving average price is $109.19 and its two-hundred day moving average price is $128.58.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ILMN. Guggenheim dropped their target price on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Canaccord Genuity Group dropped their target price on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, March 11th. Piper Sandler upped their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Finally, Royal Bank of Canada decreased their price target on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.